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Background. Alfacalcidol is efficient for treating secondary hyperparathyroidism in patients on mainten-Anaemia is one of the more constant clinical features ance haemodialysis ( HD). Little is known about the in patients on maintenance haemodialysis (HD). The direct impact of high-dose alfacalcidol on anaemia in aetiology of anaemia in these patients is multifactorial. end-stage renal failure. We therefore carried out a The major factors seem to be inappropriate low serum prospective study over 18 months to examine the direct erythropoietin, functional iron deficiency, dialysis effect of high-dose alfacalcidol on erythropoiesis in insufficiency, aluminium overload, and secondary erythropoietin (rHuEpo)-dependent anaemic patients hyperparathyroidism ( HPT ) [1] [2] [3] [4] [5] [6] [7] [8] [9] . on HD for more than 6 months with moderate hyperHigh-dose calcitriol, the active form of vitamin D, parathyroidism.
is widely used in haematological disorders [ l0-11 ] and Study design. Twelve patients received oral alfacalcidol HPT treatment [12] [13] [14] . Furthermore, in vitro and at a dosage of 6-7 mg per week and calcium carbonate other studies indicate that bone marrow erythropoietic during the first 12 months, calcium carbonate without cells have specific receptors for calcitriol, and calalfacalcidol during the next 3 months, and again citriol induces proliferation and maturation of stem alfacalcidol and calcium carbonate during the last 3 cells[4-6,10,11]. The present study was designed for months. Criteria for selection were haemoglobin <10 evaluation of direct effect of high-dose alfacalcidol on g/dl, iPTH >250 pg/ml, transferrin saturation anaemia without recombinant human erythropoietin ( TS) >25%, S-ferritin >300 mg/l, and S-aluminium (rHuEpo) throughout the study in anaemic patients <40 mg/l.
on HD with moderate HPT, who were, 1 month before, Results. Haemoglobin (Hb) and reticulocyte counts under rHuEpo, for 18 months of follow-up. increased during the first phase, decreased and returned to a baseline prior to starting vitamin D treatment in Subjects and methods the second phase, and again increased when alfaclcidol was reintroduced, whereas iPTH decreased during the Patients first 3 months of the first phase and then remained stable, as did S-calcium, which increased during Twelve patients, from a total population of 200 patients in the first 3 months and then remained constant. six haemodialysis units, on maintenance HD for at least 6 S-phosphate increased during the first and third phases, months and without rHuEpo therapy or calcitriol for at least and decreased during the second phase. Two patients 1 month before the study, iPTH >250 pg/ml (normal 55) during the first phase and one patient during the third and haemoglobin concentration ( Hb) <10 g/dl were selected.
They were eight males and four females, with a mean age phase presented hypercalcaemia; requiring a temporary 59±14 years. The mean duration of HD was 134 ± 179 discontinuation of alfacalcidol.
months. There were seven patients with the diagnosis of Conclusion. High-dose alfacalcidol is efficient in chronic glomerulonephritis, two had chronic tubulointeranaemic patients with moderate hyperparathyroidism stitial nephritis, and three were of unknown aetiology. We on maintenance HD and has a direct effect on erythro-excluded all patients with iron, folate or vitamin B 12 defipoietic cells regardless of serum calcium and iPTH ciency, serum aluminium exceeding 40 mg/l, active bleeding levels.
lesions, active untreated infection, malignancies or other causes of inflammation, and also patients with medications polysulphone dialysers, and were being managed to maintain 10.8±0.9 g/dl at 6 months, and 10 7±0 9 g/dl at 12 their Kt/V (urea) >1 and protein catabolic rate (PCR) 1-1.2 months (n.s. vs 3 months), 8.9±0.6 g/dl at 15 months g/kg/day ( Table 1 ). The average length of HD sessions was (P<0.005 vs 12 months), and 10.5±0.6 g/dl at 18 4±0.29 h (range 4-5 h). months (P<0.005 vs 15 months).There was an increase in Hb during the first 3 months P<0.005 vs before), Study design a stabilization in Hb during the next 9 months (n.s.), a decrease in Hb during the second phase (P<0.005 The study, which was for 18 months, was subdivided into vs 12 months), and a re-increase in Hb during the three phases: third phase (P<0.005 vs 15 months).
The first phase was the first 12 months during which all patients were treated with alfacalcidol and calcium carbonate. The second phase was the next 3 months, during which all Absolute reticulocyte counts (Figure 2) patients were treated with calcium carbonate without alfacalcidol for maintaining constant serum calcium and iPTH Reticulocyte counts increased during the first phase levels. The third phase was the last 3 months, during which and reached a maximum at 12 months (P<0.005 vs all patients were treated with alfacalcidol and calcium before), decreased abruptly during the second phase carbonate.
(P<0.005 vs 12 months), and re-increased during the The dose of alfacalcidol was decreased or increased weekly third phase (P<0.005 vs 15 months).
to maintain serum calcium above 2.2 mmol/l and below 3 mmol/l and serum phosphorus below 2.5 mmol/l; as was calcium carbonate which was given as phosphate chelator exclusively.
Serum iPTH, calcium and phosphorus levels (Figure 1)
There were a decrease in iPTH levels and an increment Measurements in S-calcium during the first 3 months (P<0.005 vs before) and a progressive stabilization in iPTH and
Haemoglobin, absolute reticulocyte counts, serum calcium S-calcium levels during the next 15 months (n.s.).
and serum phosphorus were monitored weekly. Serum iron, TS were assessed monthly. iPTH, serum ferritin (at least
Two patients during the first phase and one during 1 week after the last iron infusion) by radioimmunoassay, the third phase presented hypercalcaemia, necessitating cyanocobalamine, intra-and extraerythrocytic folate, serum a temporary discontinuation of alfacalcidol and calalbumin by nephelometry and serum aluminium were cium carbonate for 2 weeks. The mean serum phosmeasured quarterly. Kt/V was calculated according to phorus levels, which were statistically higher under Daugirdas [15] and PCR was calculated according to Gotch alfacalcidol (P<0.005), were within the low normal range in the second phase because of alfacalcidol discontinuation, increase in calcium carbonate dosage, Statistical analysis sustained S-PTH secretion, and normal phosphorus intake.
All data are presented as means ±standard deviation of the mean of the total measurement per period. Statistical differences between periods were calculated by two-tailed Student
Iron status, S-aluminium and S-albumin levels test, the patients acting as their own controls.
Iron status, which was assessed by TS and serum ferritin, was constant throughout the study (Figure 2 ).
Results
S-ferritin, which was higher during the second and third phases, but remained statistically insignificant None of the patients selected used other medication (n.s. vs before). TS was >25% throughout the study. known to affect erythropoiesis or bone mineral meta-S-aluminium levels were <40 mg/l during the study bolism during the study, and all patients completed period ( Table 1) . Aluminium compounds were avoided the study without any intercurrent problem. No in all patients selected, since a form of low turnover patients dropped out.
osteodystrophy and anaemia was noted with oral aluminium exposure [9, 12, 13] . Haemoglobin concentration (Figure 1) Nutritional state, which was assessed by S-albumin, was good throughout the study; as were dialysis Haemoglobin was 8.7±1.2 g/dl before treatment, 10.3±0.8 g/dl at 3 months (P<0.005 vs before), parameters (Table 1 ) . 
Alfacalcidol and calcium carbonate doses
Functional iron deficiency and aluminium overload were carefully avoided in this trial by displacing TS The dose of alfacalcidol was temporarily reduced in a towards more than 25%, S-ferritin >500 mg/l, parenfew cases from 7 to 3 or 4 mg weekly because of high teral administration of iron salt during HD sessions, serum calcium or high phosphorus levels. In absolute and calcium carbonate as exclusive phosphate values, the mean alfacalcidol dose was 6.1±1.5 mg per chelator [3] . week during the first phase and 5.8±1.2 mg per week
In agreement with other studies [14] , the selection of during the third phase; the mean calcium carbonate high-dose oral alfacalcidol engenders much inconvenidose was 8.2±2 3 g daily during the first phase, ence: (i) an important rise in S-calcium (2 patients in 10.1±2.4 g daily during the second phase, and the first phase and 1 patient in the last phase), (ii) a 7.1±3.5 g daily during the last phase.
substantial increase in S-phosphate, explaining the negative effect of alfacalcidol on long-term iPTH levels, which were not reduced to the normal range except in Iron intravenous substitution and need for transfusions four patients within the high normal range and one Intravenous iron, which was exclusively used, was patient within the low normal range, (iii) an induction indicated when TS was <25% and/or S-ferritin of adynamic bone disease, an important subject of <500 mg/l. debate, in patients within the low range iPTH concenThe mean individual intravenous ferric hydroxide trations without aluminium intake [12, 13] , and (iv) an polymaltose dose was 400±60 mg/month, increase in the Ca×P ion products, a propensity 333±49 mg/month before and during the study toward soft-tissue calcification. respectively. No patients were transfused throughout
In the second phase a higher S-calcium compared the study.
to normal (as evidenced by a higher set point ) and a lower S-phosphate were required to sustain iPTH secretion.
Discussion
We acknowledge that the number of subjects selected was small in this study and lacked a control group, but our selection criteria and study design were rigorThe present study clearly shows the positive impact of high-dose alfacalcidol on anaemia and moderate sec-ous in order to use all patients as their own controls ,and to obtain a rational conclusion from our results. ondary hyperparathyroidism in HD patients with a good iron status and efficacious dialysis parameters. We conclude that high-dose alfacalcidol is efficient in anaemic patients with moderate HPT on maintenance Previous studies in myeloplastic anaemia [10, 11] and in anaemia with end-stage renal failure on HD or HD, and has a direct effect on erythropoiesis, but its adverse effects of vitamin D must be taken into considperitoneal dialysis [4-6 ] found improvement of anaemia with high-dose alfacalcidol.
eration. Further studies are necessary to confirm these results. iPTH, which has a direct inhibitory effect on erythropoiesis, increases bone marrow fibrosis, decreases erythrocyte survival, interferes with Epo production and is a resistance factor in rHuEpo therapy, is one of References the mechanisms suggested [4-8], but in our study gesting that S-calcium is not the main factor explaining
